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Abstract 
Background: Whole Plasmodium sporozoites serve as both experimental tools and potentially as deployable vac-
cines in the fight against malaria infection. Live sporozoites infect hepatocytes and induce a diverse repertoire of 
CD8+ T cell responses, some of which are capable of killing Plasmodium-infected hepatocytes. Previous studies in Plas-
modium yoelii-immunized BALB/c mice showed that some CD8+ T cell responses expanded with repeated parasite 
exposure, whereas other responses did not.
Results: Here, similar outcomes were observed using known Plasmodium berghei epitopes in C57BL/6 mice. With the 
exception of the response to PbTRAP, IFNγ-producing T cell responses to most studied antigens, such as PbGAP50, 
failed to re-expand in mice immunized with two doses of irradiated P. berghei sporozoites. In an effort to boost 
secondary CD8+ T cell responses, heterologous cross-species immunizations were performed. Alignment of P. yoelii 
17XNL and P. berghei ANKA proteins revealed that >60 % of the amino acids in syntenic orthologous proteins are 
continuously homologous in fragments ≥8-amino acids long, suggesting that cross-species immunization could 
potentially trigger responses to a large number of common Class I epitopes. Heterologous immunization resulted in a 
larger liver burden than homologous immunization. Amongst seven tested antigen-specific responses, only CSP- and 
TRAP-specific CD8+ T cell responses were expanded by secondary homologous sporozoite immunization and only 
those to the L3 ribosomal protein and S20 could be re-expanded by heterologous immunization. In general, heter-
ologous late-arresting, genetically attenuated sporozoites were better at secondarily expanding L3-specific responses 
than were irradiated sporozoites. GAP50 and several other antigens shared between P. berghei and P. yoelii induced a 
large number of IFNγ-positive T cells during primary immunization, yet these responses could not be re-expanded by 
either homologous or heterologous secondary immunization.
Conclusions: These studies highlight how responses to different sporozoite antigens can markedly differ in recall fol-
lowing repeated sporozoite vaccinations. Cross-species immunization broadens the secondary response to sporozo-
ites and may represent a novel strategy for candidate antigen discovery.
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Background
Pre-clinical and clinical vaccine studies have demon-
strated that whole Plasmodium sporozoites can induce 
sterile protection against infectious challenge [1–5]. 
Sporozoite formulations include radiation-attenuated 
sporozoites (RAS) [3, 6], genetically attenuated para-
sites (GAP) [7] or wild-type (WT) sporozoites adminis-
tered under anti-malarial drug prophylaxis [2, 8]. Such 
approaches induce protective antibodies and T cells with 
IFNγ-producing cytotoxic T lymphocytes (CTL), which 
are particularly important for protection during the liver 
stage [9]. Plasmodium are complex eukaryotic pathogens 
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that express thousands of different proteins through-
out their lifecycle [10]. Until recently, this enormous 
array of proteins made it difficult to study antigen-spe-
cific immune responses on a large scale. Consequently, 
relatively little is known about the repertoire of T cell 
responses and to some extent antibody responses that 
target pre-erythrocytic stage antigens.
The most well-studied antigen is the circumsporozo-
ite protein (CSP) [11, 12]. CSP encounters antigen-pro-
cessing cells after being shed from the sporozoite surface 
[13] and alternatively after transport into the hepatocyte 
cytoplasm in sporozoite-invaded hepatocyte [14]. CSP 
induces protective Class I-dependent CTL responses 
[14–16] and can also induce CD4+ T cell responses [17, 
18] and major histocompatibility complex (MHC) Class 
II-dependent IgG responses [19]. While CSP-specific 
cells can induce protection when present at extremely 
high frequencies through experimental manipulations 
[12, 16, 18, 20, 21], such frequencies are not commonly 
achieved following sporozoite exposures. The CSP-based 
RTS,S vaccine in humans does not trigger strong CTL 
responses [22, 23] and instead seems to rely on anti-
bodies and CD4+ T cell responses [24] to achieve par-
tial protection [25]. Moreover, non-CSP antigens are 
increasingly appreciated as potential vaccine candidates 
since mice can be protected against challenge even in the 
absence of CSP-specific immunity [15, 26–29]. In addi-
tion to CSP, thrombospondin-related adhesive protein 
(TRAP, also called sporozoite surface protein 2 or SSP2) 
can induce CD8 + T cells [30] and TRAP-specific CD8 T 
cells can kill infected liver cells [31]. Like CSP, TRAP is 
also shed from the sporozoite surface, a process required 
for gliding motility and sporozoite infectivity [32]. These 
two proteins have been the focus of most pre-clinical 
and clinical studies of pre-erythrocytic antigens. While 
a handful of new antigens have been recently identified 
[33], the remaining antigens targeted by humoral and cel-
lular immune responses are not well understood.
Minigene library screening was recently employed in 
an effort to identify novel pre-erythrocytic antigens [34] 
and identified the L3 ribosomal protein as a target of 
the CD8 T cell response. Whereas the response to CSP 
increased with repeated sporozoite exposures in BALB/c 
mice, the response to L3 was not strongly recalled by 
subsequent sporozoite exposures. The L3-specific T cells 
were functionally cytotoxic and could be re-expanded by 
a non-sporozoite booster in the form of Listeria mono-
cytogenes recombinantly expressing the L3 epitope [34]. 
Although single dose immunizations with attenuated 
sporozoites do not usually lead to sterile protection in 
mice [35], a single immunization does achieve a signifi-
cant level of partial protection, as measured by liver bur-
den assessments [34]. Subsequent immunizations further 
increase this protective effect, indicative of gradual acqui-
sition of sterile protective immunity. At the vaccination 
stage, gradually acquired protection leading to significant 
reductions in liver burden also correlated with signifi-
cant reductions in the L3 antigen load [34]. Since L3 was 
mostly expressed in the liver and later erythrocyte stages 
but not the sporozoite stage, the acquisition of immunity 
against the sporozoites used for vaccination were reduc-
ing the immunogenicity of the vaccine for antigens that 
needed to be expressed de novo in the hepatocyte [34]. 
Here, a series of known Plasmodium berghei antigens 
were examined in C57BL/6 mice multiply immunized 
with sporozoites to determine if the distinction between 
boostable versus non-boostable responses was general-
izable beyond BALB/c mice. In addition, heterologous 
cross-species/strain immunization was tested to deter-




All animal studies were approved by the University of 
Washington Institutional Animal Care and Use Com-
mittee (IACUC protocol 4317-01). Female BALB/cj and 
C57BL/6 mice were obtained from Jackson Laboratories 
(Bar Harbor, ME, USA). A breeding pair of C57BL/6-
derived μMT mice (B6.129S2-Ighmtm1Cgn/J) were also 
obtained from Jackson Laboratories and were bred at 
the University of Washington. All mice were housed in 
standard IACUC-approved small animal facilities and 
used in compliance with IACUC-approved protocols.
Sporozoite vaccination and challenge
WT Plasmodium yoelii 17XNL, WT P. berghei ANKA 
and P. yoelii fabb/f−/− (GAP) sporozoites were obtained 
by salivary gland dissection from Anopheles stephensi 
mosquitoes reared at the Research Insectary at the 
Center for Infectious Disease Research (formerly Seattle 
Biomed, Seattle, WA, USA). Where indicated, RAS were 
generated by exposure to 10,000 rads using an X-ray irra-
diator (Rad-Source, Suwanee, GA, USA). Unless stated 
otherwise, RAS, GAP and WT sporozoites were admin-
istered by intravenous tail vein injection in a volume of 
150  μL. Multiply immunized mice were vaccinated at 
three-week intervals. Where indicated, sporozoites were 
purified using the Accudenz gradient method [36]. For 
challenge, mice were intravenously challenged with 1000 
or 10,000 WT sporozoites.
Ex vivo IFNγ enzyme‑linked immunosorbent spot 
(ELISPOT) assays
For ELISPOTs, peptides corresponding to known CD8+ 
T cell epitopes (1  µg/mL final) were combined with 
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1  ×  106 murine splenocytes by murine interferon-γ 
(IFNγ) ELISPOT (Affymetrix, Santa Clara, CA, USA) 
and cultured in antibody-coated ELISPOT plates 18 h at 
37  °C as previously reported [34]. Plasmodium berghei 
peptides used to assess responses included those for 
PbTRAP130–138 (H2-Db-restricted SALLNVDNL from 
PBANKA_1349800 TRAP [37]), PbS20318–326 (H2-Kb-
restricted VNYSFLYLF from PBANKA_1429200 
sporozoite-specific gene 20 (S20) [37]), PbGAP5041–48 
(SQLLNAKYL from PBANKA_0819000 glideosome-
associated protein 50 (GAP50) [38, 39]), PbF4 (EIYIFTNI 
from PBANKA_0416600 replication protein A1 [40]), 
PbNCY (NCYDFNNI from PBANKA_0714500 [41]) 
and PbCSP245–253 (H2-Kd-restricted SYIPSAEKI from 
PBANKA_0403200 circumsporozoite protein (CSP). 
Plasmodium yoelii peptides used to assess responses 
included those for PyCSP280–288 (H2-Kd-restricted SYVP-
SAEQI from PY03168) and PyL3 (H2-Kd-restricted 
GYKSGMSHI from PY05881 [34]). All gene identifiers 
refer to PlasmoDB names [42]. ELISPOT plates were 
developed using a colorimetric substrate as reported [34]. 
All ELISPOT wells were tested in two to three wells per 
mouse per antigen and cumulative ELISPOT data were 
evaluated using the mean spot forming units (SFU) per 
million splenocytes for each animal.
Bioinformatics analysis of class I peptide‑sized homology
FASTA files of all protein sequences were downloaded 
from PlasmoDB [42] for Plasmodium species (P. fal-
ciparum 3D7, P. vivax Sal-1, P. berghei ANKA, P. yoe-
lii 17XNL). Comparisons were made between proteins 
of P. falciparum 3D7 and P. vivax Sal1 and between the 
proteins of P. berghei ANKA and P. yoelii 17XNL. For 
each pair of species, an exhaustive search was carried 
out on the full protein sets of the two species to find all 
common 8-amino acid sequences. The search strategy 
was to loop through the first protein set using 8-amino 
acid by 8-amino acid comparisons. For the second pro-
tein set, proteins were concatenated end-to-end 100 at 
a time, with a separator symbol ($) between successive 
proteins. The concatenated string was searched using a 
sorted suffix array (reviewed in [43]). Matching 8-amino 
acid regions were then extended to find the longest exact 
matching peptide of length ≥8 amino acids. This strategy 
was implemented in a Python program. Data consist-
ing of the common peptide sequence, species 1 protein 
identifier and species 2 protein identifier were filtered 
to include syntenic orthologues only and further cat-
egorized by available expression data (e.g., sporozoite or 
liver stage). In addition, highly repetitive peptides such as 
pure runs or nearly pure runs of a single amino acid were 
removed from the database—this last criterion was espe-
cially useful for P. falciparum where asparagine repeats 
are extremely common [44]. Expression data consisted 
of mass spectrometry data from several large published 
datasets [10, 45–47] transformed by syntenic orthology 
to generate lists of proteins where the protein of interest 
or its syntenic orthologue was identified as a sporozoite 
(spz) and/or liver stage protein. Proteins were included if 
mass spectrometry data demonstrated at least one pep-
tide and one spectra minimum. Stage-specific datasets 
included P. berghei and P. yoelii salivary gland sporozoites 
[45], P. falciparum salivary gland sporozoites [10, 45, 46] 
and P. yoelii liver stage proteins [47]. The lengths of the 
homologous peptides were recorded and percent homol-
ogous sequence compared to the total encoded protein 
sequence for each species.
B cell depletion experiments
Anti-CD20 antibody (clone 5D2 IgG2a) was provided by 
Genentech. BALB/cj mice were injected with 250  μg of 
anti-CD20 one day prior to primary immunization with 
1  ×  104 purified P. yoelii RAS. Four weeks later, mice 
were injected again with anti-CD20 and then adminis-
tered a second homologous dose of 1 ×  104 purified P. 
yoelii RAS 2  days later. B cell depletion was confirmed 
by evaluating peripheral blood for the presence of B220+ 
cells in the single cell lymphocyte gate on a Canto flow 
cytometer (BD, Franklin Lakes, NJ, USA).
Liver stage Plasmodium 18S rRNA assay
At the indicated time post-challenge, mice were sacri-
ficed, and half of the total liver was excised and pulver-
ized by bead beating in 5  mL NucliSENS lysis buffer 
(bioMérieux, Durham, NC, USA). Total RNA was 
extracted by processing 100 μL of the NucliSENS buffer-
treated sample diluted 1:10 in NucliSENS lysis buffer on 
the EasyMag system (bioMérieux) as described for whole 
blood [48]. In some experiments, livers were pulverized 
in 5  mL Trizol (Life Technologies/Invitrogen, Carls-
bad, CA, USA) and total RNA was Trizol extracted as 
described [34]. RNA was subjected to RT-PCR using the 
One Step AgPath RT-PCR kit (Invitrogen) using a prede-
signed HEX-labelled mouse GAPDH RT-PCR assay (IDT 
Inc, Coralville, IA, USA) multiplexed with a Pan-Plasmo-
dium 18S rRNA assay. The Pan-Plasmodium 18S rRNA 
reagents consisted of a CalFluor Orange560-labelled Pan-
Plasmodium probe (5′[CAL Fluor Orange 560]-ACCGT
CGTAATCTTAACCATAAACTA[T(BHQ1)]GCCGA 
CTAG-3′; Biosearch Technologies, Navato, CA, USA) 
and adjacent primers (forward 5′-AAAGTTAAGGG 
AGTGAAGA-3′; reverse 5′-AAGACTTTGATTTCTCA 
TAAGG-3′) under the following conditions (45  °C for 
20 min, 95 °C for 15 min and 45 cycles of 95 °C for 20 s, 
50  °C for 30  s, 60  °C for 30  s) on a CFX96/1000C real-
time PCR machine (Biorad, Hercules, CA, USA). Data 
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were normalized to mouse GAPDH and transformed to 
relative log10 values to compare log10 copy number reduc-
tion in Plasmodium 18S rRNA versus the control group.
Results
Most malaria‑specific CD8+ T cell responses contract 
with repeated whole sporozoite immunization except for 
those targeting protective TRAP and CSP antigens
To determine if the previous finding [34] of expansion 
of CSP-specific T cells and contraction of L3-specific T 
cells in BALB/c mice was generalizable in other murine 
Plasmodium models, known P. berghei H2b epitopes 
were tested to determine the frequency of CD8+ T cell 
responses in sporozoite-immunized C57BL/6 mice. 
C57BL/6 mice were immunized one to three times with 
1–2  ×  104 P. berghei ANKA RAS at three-week inter-
vals. IFNγ responses to PbTRAP130–138, PbS20318–326, 
PbGAP5041–48, PBANKA_0416600 (PbF4), and 
PBANKA_071450 (PbNCY) were assessed by sple-
nocyte ELISPOT 6  days after the final immunization. 
Responses to PbTRAP130–138 (Fig. 1a) and to some extent 
PbS20318–326 (Fig.  1b) trended toward increased fre-
quency with multiple immunizations whereas responses 
to PbGAP5041–48 (Fig.  1c), PbF4 (Fig.  1d) and PbNCY 
(Fig.  1e) contracted. These findings are similar to what 
is found in BALB/cj mice multiply immunized with P. 
yoelii RAS (1–2  ×  104 spz/dose) where the CSP T cell 
population expands compared to that of the L3-specific 
T cells (Additional file 1: Figure S1 and [34]). These col-
lective results show that in two mouse strains and with 
two parasite species, T cell responses to preformed anti-
gens like CSP and TRAP can stabilize and even expand in 
numbers in the setting of repeated sporozoite exposure 
whereas most other antigen-specific T cells contracted. 
Most proteins whose responding T cell populations con-
tract are either absent or mostly absent from sporozoites 
and/or are more highly expressed in newly forming liver 
stage parasites.
Heterologous cross‑species immunization has the 
potential to generate a more diverse T cell repertoire
Plasmodium species share considerable amino acid 
homology. Despite this, most immunization-challenge 
models have consisted almost exclusively of homolo-
gous immunization followed by homologous challenge. 
Recently, some groups have begun to evaluate homolo-
gous P. falciparum (single strain) immunizations followed 
by heterologous challenge with a different P. falciparum 
strain in CHMI studies [49].
Since heterologous challenge circumvents some anti-
gen-specific immune responses [50], it was possible 
that a heterologous (cross-species) immunization regi-
men could expand CD8+ T cell responses against shared 
epitopes more so than a homologous regimen. To gauge 
the potential breadth of shared Class I epitopes, bio-
informatic analyses were performed to look for interspe-
cies homology of syntenic orthologues using a minimum 
homology length of 8 aa, the shortest length of a typical 
Class I MHC-binding peptide. First, coding sequences 
for all predicted proteins [P. yoelii 17XNL 7724 (3.3 × 106 
total aa), P. berghei ANKA 4952 (3.4 ×  106 total aa), P. 
falciparum 5398 (4.1 × 106 total aa), P. vivax Sal-1 5530 
(3.9 × 106 total aa)] were filtered to include only syntenic 
orthologous pairs. For P. yoelii 17XNL/P. berghei ANKA, 
Fig. 1 Multiple Plasmodium berghei RAS immunizations induce T cell responses with characteristically expanding or contracting frequencies in 
the C57BL/6 models of Plasmodium sporozoite immunization. C57BL/6 mice immunized once (1X) or twice (2X) with 1-2x104 P. berghei ANKA RAS 
respond to a PBANKA_1349800 TRAP (H2-Db-restricted TRAP130-138 SALLNVDNL), b sporozoite-specific gene 20 (S20) PBANKA_1429200 (H2-Kb 
restricted S20318-326 VNYSFLYLF), c PBANKA_0819000 secreted acid phosphatase glideosome-associated protein 50 (GAP50) (H2-Db restricted 
GAP5041-48 SQLLNAKYL), d PBANKA_0416600 replication protein A1 (PbF4 peptide EIYIFTNI) and e PBANKA_0714500 (H2-Kb-restricted PbNCY 
peptide NCYDFNNI). Bars display mean value and error bars show the 95 % confidence interval; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, 
Students t-test. For all peptides, splenocytes from naïve mice showed < 2 SFU/million
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there were 4191 pairs comprising 4166 P. yoelii 17XNL 
proteins of 2.4 × 106 total aa and 4075 P. berghei ANKA 
proteins of 2.9 × 106 total aa. For P. falciparum/P. vivax 
Sal1, there were 4777 pairs comprised of 4638 unique 
P. falciparum proteins of 3.6  ×  106 total aa and 4584 
P. vivax Sal1 proteins of 3.4 ×  106 total aa) (Additional 
file 2).
The predicted amino acid sequences for syntenic 
orthologous pairs were searched for homology of ≥8 con-
tiguous aa, corresponding to the minimum length of typ-
ical Class I MHC peptides (Table  1). Plasmodium yoelii 
17XNL/P. berghei ANKA demonstrated a higher degree 
of homology than P. falciparum/P. vivax Sal1, with 67,684 
homologous peptides in the former and just 41,417 in the 
latter across all life cycle stages. For sporozoites proteins, 
41,424 peptides were conserved for P. yoelii/P. berghei 
compared to 28,793 P. falciparum/P. vivax and at the 
liver stage 7659 were conserved for P. yoelii/P. berghei 
and 7813 for P. falciparum/P. vivax (Table 1). The higher 
degree of conservation was also reflected in longer mean 
lengths of homologous peptides (p  <  0.0001, Student’s 
two-sided t-test), longer maximum length peptides (P. 
yoelii/P. berghei 926 aa versus P. falciparum/P. vivax 438 
aa) and a larger percentage of total syntenic ortholo-
gous amino acids conserved in MHC-binding peptide-
length windows for P. berghei/P. yoelii (Additional file 3) 
compared to P. falciparum/P. vivax (Additional file  4). 
The relative per cent conservation of syntenic sequence 
increased in sporozoite proteins and increased further in 
LS proteins, suggesting that these proteins are less vari-
able between species. As expected, in this analysis the 
H2-Kd-binding CSP epitopes are not conserved between 
P. berghei and P. yoelii (two amino acid differences) and 
were not included, whereas the L3 epitope is completely 
conserved between P. berghei and P. yoelii species. As 
expected, the conserved peptides tested here (L3, S20, 
GAP50, F4, NCY) were present in the shared dataset, 
whereas the CSP and TRAP epitopes were not. Along 
these lines, both P. yoelii and P. berghei sporozoites (spz) 
could prime CD8+ T cell responses to the shared L3 
epitope in Balb/cj mice, whereas only P. yoelii spz could 
prime responses to the PyCSP epitope. Similarly, only P. 
berghei spz could prime responses to the PbCSP epitope 
(Additional file 5: Figure S2). This finding is in agreement 
with previous work showing that CTLs that target the 
PbCSP epitope can protect P. berghei spz challenge but 
not against P. yoelii spz [12].
Heterologous cross‑species immunizations achieve 
larger secondary liver infections than homologous 
immunizations
In recent work, repeated homologous immunization was 
shown to progressively reduce liver stage burdens—even 
a single P. yoelii RAS immunization reduced the next 
immunization liver burden by >90 % [34]. To determine if 
liver infection was greater following heterologous cross-
species immunization, BALB/cj mice were immunized 
homologously or heterologously and liver burden was 
measured by Plasmodium 18S rRNA RT-PCR at 44 h fol-
lowing the second immunization. Both the heterologous 
(P. berghei  →  P. yoelii) and homologous (P. yoelii  →  P. 
berghei) second doses resulted in smaller magnitude liver 
infections compared to a single dose of sporozoites given 
to naïve mice (P. yoelii) (Fig.  2a). Homologously immu-
nized mice generally had extremely low liver burdens at 
levels that approached uninfected mice in some cases. 
Heterologously immunized mice showed a smaller reduc-
tion in liver burden compared to homologously immu-
nized mice (Fig.  2a). These results indicated that there 
could be more antigen in the livers of heterologously 
Table 1 Shared 8-mer linear peptidome of rodent and human Plasmodium parasites
Pb, P. berghei ANKA; Py, P. yoelii 17XNL; Pf, P. falciparum 3D7; Pv, P. vivax Sal1; aa, amino acids
a Comparison to all stage or stage-specific syntenic proteomes. Total aa for all stages (Py 2.44 × 106 aa; Pb 2.90 × 106 aa; Pf 3.58 × 106 aa; Pv 3.42 × 106 aa), sporozoite 
stage (Py 1.46 × 106 aa; Pb 1.81 × 106 aa; Pf 2.27 × 106 aa; Pv 2.19 × 106 aa) and liver stage (Py 3.36 × 105 aa; Pb 3.42 × 105 aa; Pf 3.83 × 105 aa; Pv 3.90 × 105 aa)






Total aa conserved 
in ≥8 aa windows
% of syntenic  
proteomea (%)
Py/Pb All 67,684 25.5 926 1.72 × 106 70.5 % Py/59.3 % Pb
Pf/Pv All 41,417 15.7 438 6.49 × 105 18.1 % Pf/18.9 % Pv
Py/Pb Spz 41,424 26.9 926 1.12 × 106 All: 46.5 % Py/38.4 % Pb
Spz: 76.2 % Py/61.6 % Pb
Pf/Pv Spz 28,793 16.4 438 4.73 × 105 All: 13.2 % Pf/13.8 % Pv
Spz: 20.8 % Pf/13.8 % Pv
Py/Pb LS 7659 34.8 831 2.67 × 105 All: 10.9 % Py/9.2 % Pb
LS: 79.5 % Py/77.9 % Pb
Pf/Pv LS 7813 19.3 438 1.51 × 105 All: 4.2 % Pf/4.4 % Pv
LS: 38.6 % Pf/39.3 % Pv
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immunized mice that could potentially stimulate greater 
secondary T cell responses against shared epitopes, in 
particular against antigens not normally boosted by 
homologous immunizations.
Previous work on cross-species protection in homolo-
gously immunized C57BL/6 mice suggested that such 
protection was T cell dependent since adoptively trans-
ferred antisera generated by homologous immuniza-
tion could not confer protection against cross-species 
challenge [50]. To determine if heterologous immuni-
zation resulted in larger liver burdens by circumvent-
ing the antibody responses stimulated by the priming 
immunization, several experiments were conducted 
on the C57BL/6 and BALB/c backgrounds. The follow-
ing B-cell deficient mouse experiments were measured 
by liver-stage RT-PCR at 24  h post-immunization in 
order to separate effects of cell-mediated killing and 
antibody-mediated blockade of invasion. First, WT 
C57BL/6 mice and C57BL/6-derived μMT mice were 
compared in homologous P. berghei RAS immuniza-
tion experiments. μMT mice lack mature B cells and 
do not make antibody responses. WT C57BL/6 and 
μMT mice were immunized with P. berghei RAS once 
or twice and the parasite liver burden was measured at 
24 h after the last immunization as a measure of initial 
liver-stage infection. At 24  h post-challenge, homolo-
gously immunized B6 mice showed a reduction in liver 
burden compared to singly exposed animals (Fig.  2b). 
In contrast, there was no such reduction in B-cell defi-
cient μMT mice regardless of one or two exposures 
(Fig.  2b). This finding suggests that a single exposure 
to sporozoites elicits antibody-mediated ‘debulking’ 
of subsequent immunizations in immunocompetent 
C57BL/6 mice. μMT mice could not be used to assess 
whether the resulting increase in liver burden increased 
overall immunogenicity because repeated immuniza-
tions led to the development of small brittle spleens that 
demonstrated unacceptably high lymphocyte mortal-
ity (>80 %) upon splenocyte harvest. To test the role of 
antibodies in BALB/c mice, anti-CD20 antibodies (kind 
gift of Genentech) were used to eliminate B cells before 
each of two P. yoelii RAS immunizations in BALB/cj 
mice. Anti-CD20 antibody-treated mice showed no 
demonstrable B cells by anti-B220 staining compared 
to control mice (Additional file 6: Figure S3). Antibody-
treated, B cell-deficient BALB/c mice showed a more 
than twofold increase in parasite liver burden (+0.45 
log10 copies Plasmodium 18S rRNA) at 24 h post-chal-
lenge compared to untreated mice (Fig. 2c). Changes in 
liver burden observed in B-cell deficient mice (through 
genetic- and antibody-mediated approaches) show that 
antibodies reduce the liver burden in homologously 
immunized mice. These findings support the idea that 
heterologous immunization circumvents homologous 
antibody-dependent protection that otherwise would 
debulk the intended liver infection.
Fig. 2 Heterologous cross-species immunization increases secondary liver burden compared to homologous immunization in part by circumvent-
ing homologously directed antibody responses. a Liver burden at 44 h after single (Py), homologous (Py → Py) or heterologous (Pb → Py) RAS 
immunizations of BALB/cj mice compared to uninfected animals (none). b Liver burden at 24 h after final immunization of WT C57BL/6 or μMT mice 
with either single (Pb) or double (Pb → Pb) homologous RAS regimens. c Liver burden at 24 h after homologous RAS immunization of BALB/cj  
mice mock-treated or treated with anti-CD20 antibodies to deplete B cells. *p < 0.05,**p < 0.01, ***p < 0.001,****p < 0.0001, Students t-test. All 
doses were 1 × 104 RAS. Plasmodium 18S rRNA content was normalized to the host GAPDH mRNA and differences are expressed in log10 changes 
in parasite 18S rRNA concentration relative to the single exposure control average
Page 7 of 13Billman et al. Malar J  (2016) 15:238 
Heterologous immunization recalls some but not 
all CD8+ T cell responses that normally contract 
following homologous immunizations
With the hypothesis that heterologous cross-species 
immunization could boost the CD8+ T cell repertoire 
against shared antigens more than conventional homol-
ogous regimens, mice were immunized with two-dose 
sporozoite regimens consisting of P. yoelii 17XNL RAS 
and/or P. berghei ANKA RAS and measured CD8+ T 
cell responses to known P. yoelii and P. berghei antigens 
6 days later. Heterologously immunized BALB/cj mice (P. 
berghei RAS → P. yoelii RAS) recalled responses to L3 at 
marginally higher frequencies than by homologous vacci-
nation (P. yoelii RAS → P. yoelii RAS), although the effect 
was not statistically significant and the overall magnitude 
of these responses was extremely low (Fig.  3a). PyCSP-
specific T cell responses were not increased by heterolo-
gous immunization, consistent with the fact that PyCSP 
and PbCSP H2-Kd epitopes differ at two amino acids as 
noted above. Since late-arresting sporozoites such as P. 
yoelii fabb/f−/− GAP are more ‘fit’ and develop longer 
than P. yoelii RAS, it was possible that prolonged pre-
erythrocytic development of the P. yoelii GAP would 
result in more antigen expression. P. yoelii fabb/f−/− GAP 
is a late-arresting GAP attenuated by deletion of FabB/F, 
an important enzyme in Plasmodium fatty acid synthesis 
[51]. BALB/cj mice were immunized with P. yoelii GAP 
alone or with homologous (P. yoelii RAS → P. yoelii GAP) 
or heterologous (P. berghei RAS →  P. yoelii GAP) regi-
mens. While L3 responses contracted in homologously 
immunized mice compared to singly exposed mice, het-
erologous immunization recalled responses at signifi-
cantly higher frequencies than the homologous regimen 
(Fig.  3b). The overall magnitude of the L3 response at 
primary GAP and heterologous RAS → GAP secondary 
endpoints was also substantially higher than in RAS-only 
immunizations. This suggests that heterologous immu-
nization can achieve higher secondary liver burdens and 
that use of a late-arresting sporozoite at the secondary 
booster vaccination can likely lead to higher L3 antigen 
concentrations that induce higher secondary L3-specific 
T cell frequencies.
In C57BL/6 mice, most well-studied antigens are P. 
berghei derived, which meant that the secondary immu-
nization in heterologous C57BL/6 experiments needed 
be P. berghei to ensure fair comparison to singly exposed 
mice. As there are no late-attenuated P. berghei para-
site lines widely available, heterologous experiments in 
C57BL/6 mice aimed to achieve higher secondary anti-
gen concentrations by instead increasing the dose of RAS 
administered at the second exposure. WT C57BL/6 mice 
were immunized with nothing or with 1 ×  104 purified 
P. yoelii RAS or 1 ×  104 purified P. berghei RAS. Three 
weeks later, all mice were immunized with 8 × 104 puri-
fied P. berghei RAS and CD8+ T cell responses to known 
antigens were assessed 6  days later. PbTRAP130–138-spe-
cific responses did not decline after a second homologous 
or heterologous immunization (Fig.  4a), consistent with 
the previously observed maintenance or even boost-
ing of this cell population with re-exposure at lower 
booster doses. In this high-dose booster model and 
in contrast to what was seen in the low dose P. berghei 
RAS booster (Fig.  1b), responses to PbS20318–326 con-
tracted on secondary homologous exposure, but could 
be recalled by a high dose heterologous booster (Fig. 4b). 
Responses to PbGAP5041–48 (Fig. 4c), PbF4 (Fig. 4d) and 
PbNCY (Fig.  4e) were all highly induced by a large sin-
gle P. berghei RAS exposure but could not be recalled by 
either homologous or heterologous double exposures, 
findings consistent with the low dose homologous expo-
sure (Fig. 1c–e). These data begin to categorize the CD8+ 
T cell repertoire induced by Plasmodium sporozoites 
into responses primed but not recalled by re-exposure, 
primed and recalled by homologous re-exposure or 
Fig. 3 Heterologous immunization with late-arresting attenuated 
sporozoites leads to higher secondary CD8+ T cell responses to the 
L3 antigen in BALB/cj mice. a L3-specific responses in BALB/cj mice 
immunized homologously with P. yoelii RAS (Py/Py) or heterologously 
with P. berghei RAS followed by P. yoelii RAS (Pb/Py). Heterologous 
immunization showed a small non-significant increase in L3-specific 
responses. b L3-specific responses in BALB/cj mice immunized with 
P. yoelii fabb/f−/− GAP (PyGAP) or homologously with P. yoelii RAS 
followed by P. yoelii GAP (PyRAS/PyGAP) or heterologously with P. 
berghei RAS followed by P. yoelii GAP (PbRAS/PyGAP). Homologous 
immunization showed the typical contraction of the L3-specific 
response, whereas heterologous exposure resulted in a significant 
increase relative to homologous levels. In some cases, mice mounted 
extremely strong L3 responses following secondary heterolo-
gous exposure that were never seen following primary exposure. 
**p < 0.01, ***p < 0.001, Student’s t-test. All injections were 1 × 104 
sporozoites by intravenous route
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primed and recalled by heterologous but not homologous 
re-exposure.
Discussion
Although repeated homologous sporozoite immuniza-
tion protects humans from WT P. falciparum challenge, 
the regimen that achieves protection requires four to five 
intravenous doses of 1.35 × 105 irradiated, cryopreserved 
sporozoites at each dose [1]. Less attenuated sporozo-
ites such as late-arresting GAPs [4] or WT sporozoites 
administered under anti-malarial drug coverage [2] may 
have a dose-sparing effect but GAP vaccines have not 
yet been manufactured in a vialed format. Vialed, cryo-
preserved WT sporozoites under a concurrent drug 
treatment-vaccination approach known as CVac [52] are 
being developed but may require optimization. At this 
time, it is difficult to make a head-to-head comparison 
about the immunogenicity of PfSPZ, GAP and/or CVac-
type approaches because optimal vaccination sched-
ules have not been finalized for any of these approaches. 
Modifications that reduce dosing frequency and/or dos-
age while increasing immunogenicity (and ultimately effi-
cacy) may improve delivery of whole sporozoite vaccine 
product. This study was undertaken in the mouse model 
to evaluate sporozoites vaccination modifications that 
could generally enhance the immunogenicity of sporozo-
ite-based vaccines.
In previous work in the BALB/cj model [34], two model 
P. yoelii-derived antigens were found to induce very dif-
ferent CD8+T cell responses upon repeated sporozoite 
immunizations. The well-studied CSP antigen-induced 
cytotoxic CD8+ T cells that increased in frequency with 
multiple doses of 1 × 104 sporozoites (RAS or GAP). In 
contrast, the L3 ribosomal protein induced a comparable 
number of cytotoxic CD8+ T cells as CSP upon primary 
immunization but these responses did not increase and 
generally contracted with multiple immunizations. Here, 
the same pattern of secondary recall or contraction was 
observed for T cell responses to a panel of known P. 
berghei epitopes in C57BL/6 mice. PbTRAP130-138 (SALL-
NVDNL) is an H2-Db-restricted cytotoxic immuno-
dominant CD8+ T cell epitope in C57BL/6 mice derived 
from PBANKA_1349800 TRAP that contributes to pro-
tection against liver-stage infection [37]. PbS20318–326 
(VNYSFLYLF) is an H2-Kb-restricted but non-cyto-
toxic, non-protective CD8+ T cell epitope derived from 
PBANKA_1429200 sporozoite-specific gene 20 (S20) 
[37]. PbGAP5041–48 (SQLLNAKYL) is derived from 
PBANKA_0819000 glideosome-associated protein 50 
known as GAP50 and targeted by cytotoxic CD8+ T cells 
[38, 39] but is not protective [53]. PbGAP5041–48-specific 
cells have amongst the highest precursor frequency iden-
tified for any T cell with ~2200 PbGAP5041–48-specific 
cells per animal [54]. PbF4 (EIYIFTNI) is derived from 
PBANKA_0416600 replication protein A1 and is a blood 
stage CD8+ epitope [40]. Recently, T cells responding to 
Pb1, F4 and another epitope from PBANKA_113700/
bergheilysin (IITDFENL) were shown to damage the 
blood–brain barrier in a murine model of P. berghei-
induced cerebral malaria [39]. PbNCY (NCYDFNNI) is 
derived from PBANKA_0714500 and is the target of so-
called ‘PbT1′ T cells that have been shown to respond to 
P. berghei sporozoites and infected erythrocytes [41]. This 
antigen is encoded on sporozoites and PbT1 cells are able 
to protect mice from liver-stage challenge infection fol-
lowing a spleen-centered CD8α+ dendritic cell-depend-
ent immune response, indicating that the antigen may be 
partly cross-presented [41].
Across both BALB/c and C57BL/6 backgrounds, the 
collective data now show that antigen-specific CD8+ 
Fig. 4 Heterologous immunization with a high-dose RAS booster in C57BL/6 mice can be used to distinguish between recalled and non-recalled 
responses. Antigen-specific responses in C57BL/6 mice immunized once with 8 × 104 P. berghei RAS (PbRAS), homologously with 1 × 104 P. 
berghei RAS followed by 8 × 104 P. berghei RAS (PbRAS → PbRAS) or heterologously with 1 × 104 P. yoelii RAS followed by 8 × 104 P. berghei RAS 
(PyRAS → PbRAS). Antigens included PbTRAP (a), PbS20 (b), PbGAP50 (c), PbF4 (c) and PbNCY (e); additional identifying details are in Fig. 1 and 
“Methods” section. Bars display mean value and error bars show the 95 % confidence interval; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, 
Student’s t-test
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T cell responses to PyL3, PbS20318–326, PbGAP5041–48, 
PbF4, and PbNCY contract despite repeated immuni-
zation whereas responses to protective TRAP and CSP 
antigens remain stable or even expand. Responses that 
contract do not exclusively target late liver stage anti-
gens. As previously hypothesized [34], the failed second-
ary expansion of cells targeting proteins like L3, F4 and 
NCY may be explained by the ‘debulking’ of the second-
ary immunization dose achieved by the poly-specific 
immune response. However, PbS20 and PbGAP50 are 
both present in higher quantities in the sporozoite itself 
(Table 2), albeit at much lower concentrations than CSP 
and TRAP. The T cells responding to these antigens are 
unlikely to have functional defects that preclude their 
secondary expansion since L3 [34], PbGAP50 [53] and 
NCY [41] have all been shown to expand to extremely 
high T cell frequencies with non-parasite booster 
vaccines.
To address whether a simple ‘debulking’ model 
explained the contraction of responses to S20, GAP50, 
F4, and NCY, heterologous immunization was tested 
to determine if this approach could secondarily expand 
these specific T cell populations. Bio-informatic analy-
sis demonstrated that there is a considerable amount of 
protein sequence homology that constitutes peptides 
of sufficient length to be Class I MHC targets. To pur-
sue this approach experimentally, BALB/cj mice immu-
nized with P. berghei RAS then P. yoelii RAS achieved 
larger liver burdens upon secondary immunization as 
compared to mice immunized twice with P. yoelii RAS. 
Although a major goal of vaccine developers is to pro-
duce a malaria vaccine that achieves cross-species pro-
tection, the imperfect cross-species immunity achieved 
after a single immunization with just one species means 
that the vaccine ‘take’ upon secondary heterologous 
immunization is improved. This debulking is at least par-
tially due to antibodies directed against homologous par-
asites since circumventing such antibodies can increase 
liver burden upon secondary vaccination. The T cell rep-
ertoire is potentially extremely large and could benefit 
from secondary boosting of responses to shared epitopes. 
Although L3 and PbS20 are both non-protective, these 
antigens could be recalled by heterologous but not 
homologous immunization. The assumption is that these 
antigens are emblematic of a class of antigens that do not 
re-expand due to debulking of the secondary immuniza-
tion by the immunity achieved by primary immunization. 
If this class of antigens contains as yet undiscovered pro-
tective targets, heterologous immunization could accel-
erate their discovery. L3 responses were more vigorously 
recalled by secondary heterologous immunization with a 
late-arresting GAP compared to the early-arresting RAS 
approach. Thus, a more ‘fit’ parasite may also improve 
recall of liver-stage antigens. It seems unlikely that the 
degree of attenuation would profoundly affect responses 
to antigens that are primarily pre-formed in the sporozo-
ite. This may explain why abundant pre-formed CSP and 
TRAP antigens expand responses while less abundant 
pre-formed antigens like PbS20 and PbGAP50 do not. 
The strong primary responses to PbS20 and PbGAP50 
and lack of secondary homologous responses also sug-
gest that these responses probably depend on sufficient 
hepatocyte infection. Heat-killed sporozoites can induce 
responses to CSP but at considerably lower frequencies 
than with live sporozoites [34, 55], which also implies 
that responses to CSP also depend on liver infection. 
Responses to the CSP and TRAP epitopes tested here 
did not benefit from heterologous immunization because 
Table 2 Comparison of immunogenicity data to available mass spectrometry-based expression data
Hom homologous; Het heterologous; NA not applicable; ND not detected
a PyCSP SYVPSAEQI vs. PbCSP SYIPSAEKI; PyTRAP SALLVVDTL vs. PbTRAP SALLNVDNL, amino acid differences underlined
b Number of spectra detected for Py (P. yoelii) and Pf (P. falciparum) orthologues of the tested antigen based on mass spectrometry of sporozoites as described in [45]
c Change in mRNA transcription for 24 h LS:sgSPZ or 40 h LS:sgSPZ based on [47] and PlasmoDB [42]
d Py protein truncated compared to Pb protein
Antigen Epitope MHC Protective? Conserved 
in Pb/Py?
Recall? No. spectra in  
Py/Pf spzb  
(Py rank/Pf rank)




(24/40 h LS vs 
sgSPZ)cHom Het
PyCSP SYVPSAEQI H2Kd Yes Noa Yes NA 549/1460 (22/5) 166/140 (1/1) ND/ND
PbTRAP SALLNVDNL H2Db Yes Noa Yes NA 1437/2164 (13/4) 16/1 (10/22) −1.91/−3.01
PbS20 VNYSFLYLF H2 Kb No Yes No Yes 536/652 (61/44) ND/5 (NA/11) ND/ND
PyL3 GYKSGMSHI H2Kd No Yes No Yes 291/82 (89/402) ND/ND (NA/NA) 3.00/2.88
PbGAP50 SQLLNAKYL H2Db No Yes No No 390/584 (51/24) ND/ND (NA/NA) 1.31/–1.08
PbF4 EIYIFTNI H2b No Yes No No 46/84 (630/481) ND/ND (NA/NA) ND/ND
PbNCY NCYDFNNI H2b No Nod No No ND/ND (NA/NA) ND/ND (NA/NA) ND/ND
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there are amino acid differences between the species that 
preclude cross-reactive responses by species-specific T 
cells. Heterologous RAS immunization increased the 
secondary response to the conserved PbS20 antigen. For 
some conserved antigens however (PbGAP50, F4, NCY), 
even heterologous RAS immunization did not lead to 
secondary recall, suggesting that these antigens may not 
be of sufficient quantity even when the liver burden is 
modestly increased by heterologous exposure.
How much of the Pb20 and GAP50 antigens come 
from sporozoite versus intrahepatic liver expression is 
unknown. Mass spectrometry data shows that peptides 
from P. falciparum S20 can also be found on the sur-
face of sporozoites [45] and it is possible that secondary 
recall is enhanced by antigen surface exposure in addi-
tion to heterologous RAS exposure. Little is known about 
the role of GAP50 in the sporozoite. Although GAP50 
peptides are found in sporozoites [45], GAP50 is princi-
pally expressed in blood and gametocyte stages. In the 
blood, GAP50 is a constituent protein of the glideosome, 
an actin-myosin motor complex critical for erythro-
cyte invasion [56–58]. GAP50 expression continues into 
gametocytes [59], where its interaction with factor H [59] 
is being targeted as a candidate transmission blocking 
strategy [60]. At this time, it remains unknown whether 
a late-arresting/less-attenuated sporozoite would second-
arily improve recall responses for GAP50 and other anti-
gens tested in C57BL/6 mice.
The type of bio-informatic analysis conducted here has 
not been previously reported. Previous work has shown 
that rodent Plasmodia (P. yoelii/P. berghei) are evolution-
arily much closer to one another than P. falciparum/P. 
vivax [61–65]. P. yoelii/P. berghei both arise from a 
rodent Plasmodium clade whereas P. falciparum is in the 
hominid clade and P. vivax in the monkey clade [66, 67]. 
Not surprisingly, there was greater amino acid homol-
ogy of sufficient lengths to constitute potential class I 
MHC peptides (≥8 amino acids) for P. yoelii/P. berghei 
compared to P. falciparum/P. vivax. Nonetheless, the 
listings of shared syntenic peptides may help to identify 
protein targets that are in the right time and place to be 
T cell targets in heterologously immunized mice. These 
peptides also constitute one strategy for developing pan-
Plasmodium T cell vaccines. Given the large evolution-
ary distance between P. falciparum and P. vivax, more 
closely related P. falciparum strains should also be evalu-
ated. A number of these P. falciparum strains are now 
available for CHMI studies (e.g., P. falciparum 7G8 and 
P. falciparum NF135.C10) and will certainly share many 
more homologous syntenic peptides with P. falcipa-
rum than for the P. falciparum/P. vivax pair. Continued 
bio-informatics and experimental analysis of common 
peptides between species and strains may reveal novel 
strategies for developing malaria vaccines against one or 
more of the human-infecting strains.
One potential limitation of this study is that the infec-
tivity of P. yoelii and P. berghei for mice differs. P. berghei 
infectivity is generally greater than P. yoelii in C57BL/6 
mice whereas P. yoelii is more infectious in BALB/c mice 
(reviewed in [68]). However, the same number of para-
sites was administered regardless of species since there 
is no clear method for titrating the dose of one species 
against the other. The less infective species was used as 
the priming dose (P. yoelii in C57BL/6 mice or P. berghei 
in BALB/c mice). In addition, the same species was 
always used as the final dose, thereby minimizing the 
infectivity difference at the time of measurement. None-
theless, infectivity differences may need to be accounted 
for in efforts to design optimally protective vaccination 
regimens. For instance, it may be desirable to use the 
most infectious species first to prime a larger number of 
responses or it may prove better to use the more infec-
tious sporozoites secondarily to induce a larger recall 
response.
Conclusion
In summary, these data categorize CD8+ T cell responses 
induced by Plasmodium sporozoites into (a) those 
primed but never recalled by sporozoite re-exposure; (b) 
primed and recalled by homologous sporozoites; or, (c) 
primed and recalled by heterologous but not homologous 
re-sporozoites. The next phase of this work is to deter-
mine how heterologous immunizations affect antibody 
responses and to determine if two-dose heterologous 
or combination dose immunizations can be designed 
to achieve sterile protection. A possible strategy is to 
prime mice or humans with sporozoites of a single spe-
cies or strain and then boost mice with that same strain 
plus sporozoites from an additional species or a dif-
ferent strain. In addition, if low abundance and/or late 
liver stage antigens are found to be important through 
sporozoite- or subunit-based experimentation, sporo-
zoite-based vaccines could potentially be empowered 
to expand such responses if recombinant parasites were 
engineered to express such live stage antigens earlier as 
pre-formed proteins in salivary gland sporozoites.
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vivax Sal1 syntenic orthologue pairs for all lifecycle stages, sporozoite 
stage and liver stage proteins.
Additional file 5: Figure S2. P. berghei and P. yoelii sporozoites trigger 
the same IFNγ-producing L3-specific T cell responses. (A–B) BALB/cj mice 
were immunized with 2.5x104 WT P. yoelii 17XNL (black bars) or P. berghei 
ANKA (open bars) sporozoites under chloroquine treatment (0.8 mg chlo-
roquine ip daily). Six days post-immunization, splenocytes were assessed 
for PyCSP- and L3-specific responses by IFNγ ELISPOT. (A) Examples of 
IFNγ spots for each condition and (B) Mean responses to PyCSP and PyL3 
peptides for both P. yoelii and P. berghei species. PyCSP responses to P. 
berghei sporozoites versus P. yoelii sporozoites was significantly different 
(p <0.05 Student’s t-test). (C) BALB/cj mice were immunized with 1x104 P. 
berghei ANKA RAS and splenocyte responses to the PyCSP (SYVPSAEQI) 
and PbCSP (SYIPSAEKI) epitopes were assessed six days post immuniza-
tion by IFNγ ELISPOT. Error bars in B-C are 95% CI.
Additional file 6: Figure S3. Near total loss of B220+ B cells from 
peripheral blood following anti-CD20 antibody treatments in BALB/cj 
mice. Percentage of B220+ B cells in peripheral blood following mock or 
anti-CD20 antibody treatment of mice undergoing sporozoite immuniza-
tion. Anti-CD20 antibody treatment resulted in near total loss of B cells 
from the peripheral blood. *** p <0.001, Student’s t-test.
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